This phase III trial is comparing the effectiveness of two treatments (chemotherapy + immunotherapy, versus the best available therapy) in myelofibrosis patients who have got worse or not responded to previous treatment.
This trial is treating patients with myelofibrosis.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Eligible patients will be randomised to one of two groups (Arm A or Arm B). Patients in Arm A will receive navitoclax tablets once daily and ruxolitinib tablets twice daily; and patients in Arm B will receive one of the best available therapy options, determined by the investigator.
Recruiting Hospitals Read More